Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company's Single-Dose Mpox and Smallpox Vaccine Candidate
Portfolio Pulse from
Tonix Pharmaceuticals has received a grant from the Medical CBRN Defense Consortium to develop TNX-801, a single-dose vaccine candidate for Mpox and Smallpox. This comes as the WHO declares the spread of Mpox a public health emergency.
March 10, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals received a grant from the MCDC to develop TNX-801, a vaccine for Mpox and Smallpox, amid WHO's emergency declaration on Mpox spread.
The grant from MCDC is a positive development for Tonix Pharmaceuticals as it supports the advancement of TNX-801, a vaccine candidate for Mpox and Smallpox. The WHO's declaration of Mpox as a public health emergency highlights the urgency and potential demand for such a vaccine, likely boosting investor confidence and positively impacting TNXP's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100